Overview

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Status:
RECRUITING

Trial end date:
2030-07-01

Target enrollment:

Participant gender:

Summary

To learn if the drug combination of BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab can help to control advanced or metastatic MSS-CRC.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Strategic Alliance

Treatments:

Bevacizumab
Nivolumab
trifluridine tipiracil drug combination